Letter: tacrolimus may be hazardous in decompensated autoimmune liver disease with hyperbilirubinemia-authors' reply

Affiliations

¹ Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands.
² Institute of Liver Studies, King's College Hospital, London, UK.

Comment

Y S de Boer et al. Aliment Pharmacol Ther. 2018 Jun.

. 2018 Jun;47(11):1568-1569.

doi: 10.1111/apt.14651.

¹ Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands.
² Institute of Liver Studies, King's College Hospital, London, UK.

No abstract available

Comment on

Expert clinical management of autoimmune hepatitis in the real world.
Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Liberal R, et al. Aliment Pharmacol Ther. 2017 Mar;45(5):723-732. doi: 10.1111/apt.13907. Epub 2016 Dec 22. Aliment Pharmacol Ther. 2017. PMID: 28004405
Letter: tacrolimus may be hazardous in decompensated autoimmune liver disease with hyperbilirubinaemia.
Shen Y, Fan X, Yang X, Yang L. Shen Y, et al. Aliment Pharmacol Ther. 2018 Jun;47(11):1566-1568. doi: 10.1111/apt.14630. Aliment Pharmacol Ther. 2018. PMID: 29878422 No abstract available.